This Article  • Extract  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Biomaterials and Implants  • Transplantation, Other  • Alert me on articles by topic

Corey S. Mass, MD

Arch Facial Plast Surg. 2001;3:103.

Dr Sclafani et al are to be commended in their attempt to better characterize the behavior of implanted homograft dermis. Their study demonstrates expected remodeling seen in all tissue grafts as well as benefits of tissue compliance and compatibility. As it relates to the comparison to collagen, the description "clearly superior" might be overstated. An acelluar dermal graft (Alloderm; LifeCell Corp, Branchburg, NJ) shows clearly longer persistence, but is considerably more technically difficult and cannot be done as a simple office visit. Patients who receive a homograft dermal-implant also have a longer recovery. One must conclude that for intermediate-term augmentation 6 to 15 months of an acellular dermal graft is a good option. But for short-term improvements with minimal patient "downtime," intradermal type I bovine collagen cross-linked with glutaraldehyde (Zyplast; Collegen Corp, Palo Alto, Calif) or human tissue (Dermalogen Human Tissue Matrix; Collagenesis Inc, Beverly, Calif) are better options.

850 Parnassus Ave
Suite 207
San Francisco, CA 94143
(e-mail: csmaa{at}orca.ucsf.edu

RELATED ARTICLE

Evaluation of Acellular Dermal Graft (AlloDerm) Sheet for Soft Tissue Augmentation: A 1-Year Follow-up of Clinical Observations and Histological Findings
Anthony P. Sclafani, Thomas Romo III, Andrew A. Jacono, Steven A. McCormick, Rubina Cocker, and Andrew Parker
Arch Facial Plast Surg. 2001;3(2):101-103.
ABSTRACT | FULL TEXT